Results 191 to 200 of about 3,292,689 (405)

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Pituitary tumors. Current concepts in diagnosis and management. [PDF]

open access: green, 1995
David C. Aron   +2 more
openalex  

Figure S5 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors [PDF]

open access: gold, 2023
Mari C. Vázquez‐Borrego   +22 more
openalex   +1 more source

From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.

open access: yesEndocrine-Related Cancer, 2017
Sylvia L. Asa   +24 more
semanticscholar   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang   +18 more
wiley   +1 more source

Pituitary tumor registry: a multidisciplinary program protocol. [PDF]

open access: yesJ Diabetes Metab Disord, 2023
Mohseni S   +7 more
europepmc   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

open access: yesBritish Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun   +2 more
wiley   +1 more source

Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement [PDF]

open access: gold, 2015
Erika Peverelli   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy